Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04949191 · ClinicalTrials.gov registry record · Phase 2
The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.
A Phase 2 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT04949191 is a Phase 2 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 10 participants.
The verdict
NCT04949191, a Phase 2 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
Safety and tolerability of pemigatinib.in monotherapy or combination in patients that have participated in a previous parent study to treat advanced malignancies.
Interventions
- DRUG Pembrolizumab
- DRUG Retifanlimab
- DRUG Pemigatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-07-08 |
| Est. Completion | 2024-04-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04949191
The ClinicalTrials.gov registry entry for NCT04949191 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT04949191 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04949191 about?
NCT04949191 is a clinical study titled "The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.". Safety and tolerability of pemigatinib.in monotherapy or combination in patients that have participated in a previous parent study to treat advanced malignancies.
What is the current status of trial NCT04949191?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2021-07-08. Estimated completion is 2024-04-11.
What interventions are being tested in trial NCT04949191?
The interventions under investigation include: Pembrolizumab (DRUG), Retifanlimab (DRUG), Pemigatinib (DRUG).
Who is sponsoring clinical trial NCT04949191?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.